中国积极响应联合国发起的全球人道主义应对计划，向150多个国家和国际组织提供物资援助，向200多个国家和地区出口防疫物资，对外共提供了3200多亿只口罩、39亿件防护服、56亿人份检测试剂盒。中国支持世卫组织近期发布的《全球疫苗接种战略》，践行将疫苗作为全球公共产品重要宣示，截至2021年10月中旬已向全球100多个国家和国际组织提供了超过15亿剂新冠疫苗，为建立全球免疫屏障作出重要贡献。2020年10月，中国加入世卫组织主导的“新冠疫苗实施计划”，呼吁多边金融机构为发展中国家采购和生产疫苗提供包容性融资支持。2021年中国国药集团、科兴公司疫苗获得世卫组织紧急使用认证，于7月列入“实施计划”采购库，并达成长期供货合同。中国决定向“新冠疫苗实施计划”捐赠1亿美元，用于向发展中国家分配疫苗，并再向发展中国家无偿捐助1亿剂疫苗。中国已宣布支持新冠疫苗知识产权豁免，并呼吁各国通过开展联合研发、授权生产和技术转让等方式进一步加强疫苗产能国际合作，采取切实可行措施提升发展中国家疫苗产能。

China actively responded to the UN-initiated Global Humanitarian Response Plan, providing assistance in kind to over 150 countries and international organizations and exporting medical supplies to over 200 countries and regions. In total, it has extended to the world over 320 billion masks, 3.9 billion protective suits and 5.6 billion testing kits. China supports the Strategy to Achieve Global COVID-19 Vaccination by mid-2022 launched recently by the WHO, and has honored its commitment of making vaccines a global public good. As of mid-October 2021, China has contributed over 1.5 billion doses of COVID-19 vaccines to over 100 countries and international organizations, contributing significantly to building a global immunity defence. In October 2020, China joined the WHO-led COVAX Facility, and called on multilateral financial institutions to provide inclusive financing support for developing countries in their procurement and production of vaccines. In 2021, vaccines produced by the China National Pharmaceutical Group (Sinopharm) and Sinovac were granted WHO Emergency Use Listing (EUL) and added to the COVAX Facility procurement pool in July of the same year. The two companies have concluded long-term supply agreements as well. China has decided to donate US$100 million to COVAX for vaccine distribution among developing countries. It will donate an additional 100 million doses of vaccines to fellow developing countries. China has announced support for waiving intellectual property rights on COVID-19 vaccines, and called on countries to further strengthen international cooperation on vaccine production capacity through joint research, authorized production, technology transfer and other means, and take feasible measures to improve the production capacity of developing countries.